Instruction for use: Herpferon

Dosage form: Ointment for topical and topical application

Active substance: Interferonum alpha-2b + Acyclovirum + Lidocainum

ATX

D06BB Antiviral drugs

Pharmacological groups

Antiviral agent for topical use [Interferon in combination]

Antiviral for topical use [Antiviral (other than HIV) drugs in combination]

The nosological classification (ICD-10)

A60 Anogenital herpetic viral infection [herpes simplex]: Herpes simplex genitalis; Banal recurrent genital herpes; Secondary genital herpes; Genital herpesvirus infection; Genital herpetic infections; Genital herpes; Herpes genitalia; Genital herpes; Herpes simplex organs; Herpetic lesions of the mucocutaneous urinary organs; Herpetic lesions of the genitals; Primary genital herpes; Primary herpes simplex; Simple herpes extragenital and genital localization; Recurrent genital herpes; Recurrent herpes of genital organs; Herpes of the lips and genitals

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B00.0 Herpetic Eczema: Herpes Skin; Herpes on the skin; Eczema herpetiform Kaposi; Acute herpetic skin disease; Primary herpetic infection of the skin and mucous membranes; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Herpetic infection of the skin; Herpetic lesions of the skin; Herpetic dermatitis; Herpetic lesions of the skin; Herpetic lesions of the skin and mucous membranes; Recurrent herpetic infection of the skin; Simple skin herpes; Herpes-viral infections; Herpetic infection; Herpetic infections; Herpetic lesions; Latent herpetic infection; Neonatal herpes; Recurrent herpetic infection; Chronic recurrent herpesvirus infection; Chronic recurrent herpetic infection

B00.2 Herpetic gingivostomatitis and pharyngotongzillitis: Herpetic gingivostomatitis; Herpetic gingivitis; Herpetic gingivitis with extensive erosions; Herpetic gingivitis with extensive ulcers; Herpetic stomatitis; Herpetic stomatitis with extensive erosion; Herpetic stomatitis with extensive ulcers; Angina herpetica; Herpetic lesions of the skin and mucous membranes

B00.9 Herpetic infection, unspecified: Herpes face; Herpes mucous membranes; Herpes-viral infections; Herpes-viral infections of various localizations; Herpetic infection; Herpetic infections; Herpetic lesions; Latent herpetic infection; Neonatal herpes; Recurrent herpetic infection; Chronic recurrent herpesvirus infection; Chronic recurrent herpetic infection; Acute herpetic disease of the mucous membranes; Recurrent herpes

B02 Shingles [herpes zoster]: Herpes zoster; Herpes zoster; Shingles Herpes; Localized shingles; Infection caused by the herpes zoster virus; Shingles

Composition

Ointment for topical and topical application 1 g

Active substances: Interferon alfa-2b human recombinant not less than 20 000 ME

Acyclovir 30 mg

Lidocaine hydrochloride 10 mg

Auxiliary substances: methylparahydroxybenzoate - 2 mg; Macrogol 1500 - 290 mg; Macrogol 400 - 660 mg

Description of dosage form

Ointment: white or white with a creamy shade of color with a weak specific odor.

Pharmachologic effect

Mode of action - antiviral, anti-inflammatory, immunomodulating, locally anesthetic.

Pharmacodynamics

Herpferon®, an ointment for topical and topical use, is a combined preparation that has antiviral, anti-inflammatory, immunomodulating and analgesic effects.

Interferon alfa-2b human recombinant has a pronounced antiviral activity (suppresses replication of the virus in infected cells) and immunomodulating effect (enhancement of phagocytic activity of macrophages in lesions).

Acyclovir has a pronounced antiviral effect. Highly active against Herpes simplex virus type 1 and type 2 and virus causing varicella and herpes zoster (Varicella zoster).

Lidocaine has a local anesthetic and moderate antipruritic effect.

The combination of active ingredients provides a more pronounced anti-herpetic effect: prevents the formation of new elements of the rash, reduces the likelihood of cutaneous dissemination, accelerates healing, and reduces pain.

Pharmacokinetics

When using ointment systemic absorption is low: with intact skin, absorption is minimal, in the blood and urine is not determined, with the affected skin - moderate absorption.

Indications of the drug Herpferon

Primary and recurrent herpetic lesions of the skin and mucous membranes;

genital herpes;

Herpes zoster.

Contraindications

Hypersensitivity to the components of the drug.

Application in pregnancy and breastfeeding

Data on the use of the drug during pregnancy and during lactation are not available. Therefore, the use of the drug in these categories of patients should only be if the expected therapeutic effect exceeds the risk of development of possible side effects.

Side effects

It is possible to peel the skin in a place of prolonged application of the ointment.

Interaction

The drug is compatible and well combined with anti-inflammatory and immunomodulating drugs.

Dosing and Administration

Locally, externally.

The drug Herpferon® is applied to the affected areas of the skin and mucous membranes with a thin layer 5 times a day at intervals of 4 hours. The duration of the course of treatment is 5-10 days.

Overdose

Cases of drug overdose have not been identified.

Special instructions

The effectiveness of drug treatment will be higher the earlier it was started (at the first signs of infection).

Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions. Does not affect the ability to drive a vehicle or to carry out potentially dangerous activities requiring special attention and quick reactions (including working with moving mechanisms).

Release form

Ointment for local and external use. In aluminum tubes with bush on 5, 10 or 30 g. In a pack of cardboard 1 tuba.

Manufacturer

ZAO "Firn M". Moscow

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Herpferon

At a temperature of 2-8 ° C.

Keep out of the reach of children.

The shelf life of the drug Herpferon

2 years.

Do not use beyond the expiration date printed on the package.